肝硬化门脉高压症患者血清胃蛋白酶原Ⅰ、Ⅱ与胃泌素-17的变化及意义  

Changes and Significance of Serum PepsinogenⅠ,Ⅱand Gastrin-17 in Patients with Liver Cirrhosis and Portal Hypertension

作　　者：邵玲玲[1] SHAO Ling-ling(Department of Laboratory Medicine,Rudong County People's Hospital,Rudong,Jiangsu Province,226400 China)

机构地区：[1]江苏省如东县人民医院检验科,江苏如东226400

出　　处：《系统医学》2020年第14期44-46,共3页Systems Medicine

摘　　要：目的探究肝硬化门脉高压症患者血清PGⅠ、Ⅱ(胃蛋白酶原Ⅰ、Ⅱ)与G-17(胃泌素-17)的变化及意义。方法选取该院2017年1月—2019年8月收治的80例肝硬化门脉高压症患者为研究对象,视作观察组,同时选取同时期在该院检查的50名健康体检者为对照组,两组研究对象血清PGⅠ、Ⅱ、G-17含量均采用ELISA(酶联免疫吸附试验)进行测定,对比各组测定值差异。结果观察组G-17、血清PGⅠ、Ⅱ含量分别为(22.28±0.18)pmol/L、(148.98±6.28)μg/L、(15.18±6.96)μg/L,均高于对照组,PGR为(11.85±4.08)低于对照组(t=601.775、48.233、6.483、2.201,P<0.05)。结论肝硬化门脉高压症可能会对血清PGⅠ、Ⅱ、G-17含量产生影响,血清G-17浓度和肝功能分级存在一定相关性。Objective To investigate the changes and significance of serum PGⅠ,Ⅱ(pepsinogenⅠ,Ⅱ)and G-17(gastrin-17)in patients with cirrhosis and portal hypertension.Methods Eighty patients with cirrhosis and portal hypertension who were admitted to the hospital from January 2017 to August 2019 were selected as the research object,and were selected as the observation group.At the same time,50 healthy patients who were examined in our hospital during the same period were selected as the control group.The serum PGⅠ,Ⅱand G-17 contents of the two groups of subjects were measured by ELISA(enzyme-linked immunosorbent assay),and the difference between the measured values of each group was compared.Results The content of G-17 and serum PGⅠandⅡin the observation group were(22.28±0.18)pmol/L,(148.98±6.28)μg/L and(15.18±6.96)μg/L,which were higher than the control group,and the PGR was(11.85±4.08),lower than the control group(t=601.775,48.233,6.483,2.201,P<0.05).Conclusion Cirrhotic portal hypertension may affect the content of serum PGⅠ,Ⅱand G-17.There is a certain correlation between serum G-17 concentration and liver function grade.

关 键 词：肝硬化 门脉高压症 血清胃蛋白酶原 胃泌素 变化 

分 类 号：R446.1[医药卫生—诊断学]